Literature DB >> 29215435

Noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver in USA.

Karn Wijarnpreecha1, Charat Thongprayoon1, Melissa Scribani2, Patompong Ungprasert3,4, Wisit Cheungpasitporn5.   

Abstract

BACKGROUND/AIMS: Studies have shown that nonalcoholic fatty liver disease (NAFLD) is associated with an increased risk of chronic kidney disease (CKD). However, it is unknown whether severe liver fibrosis is associated with a higher prevalence of CKD among NAFLD. We examined the diagnostic performance of noninvasive fibrosis markers in identifying prevalent CKD among NAFLD.
METHODS: This study represents an analysis of the National Health and Nutrition Examination Survey conducted in the USA between 1988 and 1994. NAFLD was defined by ultrasonographic evidence of hepatic steatosis without other liver diseases. CKD was defined by estimated glomerular filtration rate less than 60 ml/min/1.73 m. The presence and severity of hepatic fibrosis were determined by the NAFLD fibrosis score (NFS), FIB-4 score, APRI score, and BARD score. Multiple logistic regression was performed to generate odds ratios (ORs) and receiver operating characteristic curves were used to assess the predictive values of each marker.
RESULTS: A total of 4142 individuals with NAFLD were included; 200 (4.8%) had CKD. The area under the receiver operating characteristic curves was 0.77, 0.75, 0.62, and 0.51 for the multivariable equation with FIB-4, NFS, BARD, and APRI score, respectively. Compared with patients with a low probability of developing advanced liver fibrosis, individuals with a high probability of developing fibrosis showed significantly increased odds of CKD as estimated by NFS (adjusted OR: 4.92, 95% confidence interval: 2.96-8.15) and FIB-4 (adjusted OR: 2.27, 95% confidence interval: 1.05-4.52).
CONCLUSION: Advanced liver fibrosis, defined by NFS and FIB-4 scores, is associated independently with CKD among individuals with NAFLD. FIB-4 is the best predictor of an increased risk of prevalent CKD.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29215435     DOI: 10.1097/MEG.0000000000001045

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  9 in total

1.  FIB-4 index-based surveillance for advanced liver fibrosis in diabetes patients.

Authors:  Nozomi Kawata; Hirokazu Takahashi; Shinji Iwane; Kanako Inoue; Motoyasu Kojima; Michiko Kohno; Kenichi Tanaka; Hitoe Mori; Hiroshi Isoda; Satoshi Oeda; Yayoi Matsuda; Yoshiaki Egashira; Jyunichi Nojiri; Hiroyuki Irie; Yuichiro Eguchi; Keizo Anzai
Journal:  Diabetol Int       Date:  2020-07-09

Review 2.  INASL-ISN Joint Position Statements on Management of Patients with Simultaneous Liver and Kidney Disease.

Authors:  Anil Arora; Ashish Kumar; Narayan Prasad; Ajay Duseja; Subrat K Acharya; Sanjay K Agarwal; Rakesh Aggarwal; Anil C Anand; Anil K Bhalla; Narendra S Choudhary; Yogesh K Chawla; Radha K Dhiman; Vinod K Dixit; Natarajan Gopalakrishnan; Ashwani Gupta; Umapati N Hegde; Sanjiv Jasuja; Vivek Jha; Vijay Kher; Ajay Kumar; Kaushal Madan; Rakhi Maiwall; Rajendra P Mathur; Suman L Nayak; Gaurav Pandey; Rajendra Pandey; Pankaj Puri; Ramesh R Rai; Sree B Raju; Devinder S Rana; Padaki N Rao; Manish Rathi; Vivek A Saraswat; Sanjiv Saxena; Praveen Sharma; Shivaram P Singh; Ashwani K Singal; Arvinder S Soin; Sunil Taneja; Santosh Varughese
Journal:  J Clin Exp Hepatol       Date:  2020-10-09

Review 3.  Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect.

Authors:  Rajiv Heda; Masahiko Yazawa; Michelle Shi; Madhu Bhaskaran; Fuad Zain Aloor; Paul J Thuluvath; Sanjaya K Satapathy
Journal:  World J Gastroenterol       Date:  2021-05-07       Impact factor: 5.742

4.  High FIB4 index is an independent risk factor of diabetic kidney disease in type 2 diabetes.

Authors:  Haruka Saito; Hayato Tanabe; Akihiro Kudo; Noritaka Machii; Moritake Higa; Satoshi Yamaguchi; Gulinu Maimaituxun; Kazumichi Abe; Atsushi Takahashi; Kenichi Tanaka; Koichi Asahi; Hiroaki Masuzaki; Hiromasa Ohira; Junichiro J Kazama; Michio Shimabukuro
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

5.  Response to letter to the editor by Kawada on "Association between nonalcoholic fatty liver disease with advanced fibrosis and stroke".

Authors:  Neal S Parikh; Jose Gutierrez
Journal:  J Neurol Sci       Date:  2019-11-07       Impact factor: 4.553

6.  Increased end-stage renal disease risk in patients with inflammatory bowel disease: A nationwide population-based study.

Authors:  Seona Park; Jaeyoung Chun; Kyung-Do Han; Hosim Soh; Kookhwan Choi; Ji Hye Kim; Jooyoung Lee; Changhyun Lee; Jong Pil Im; Joo Sung Kim
Journal:  World J Gastroenterol       Date:  2018-11-14       Impact factor: 5.742

7.  Association between liver stiffness measurement by transient elastography and chronic kidney disease.

Authors:  Ya-Ju Chan; Shy-Shin Chang; Jenny L Wu; Sen-Te Wang; Cheng-Sheng Yu
Journal:  Medicine (Baltimore)       Date:  2022-01-28       Impact factor: 1.889

Review 8.  Influence of Nonalcoholic Fatty Liver Disease on the Occurrence and Severity of Chronic Kidney Disease.

Authors:  Ziwen Tao; Yueyue Li; Baoquan Cheng; Tao Zhou; Yanjing Gao
Journal:  J Clin Transl Hepatol       Date:  2021-09-22

9.  Renal Tubular Damage Marker, Urinary N-acetyl-β-D-Glucosaminidase, as a Predictive Marker of Hepatic Fibrosis in Type 2 Diabetes Mellitus.

Authors:  Hae Kyung Kim; Minyoung Lee; Yong-Ho Lee; Eun Seok Kang; Bong-Soo Cha; Byung-Wan Lee
Journal:  Diabetes Metab J       Date:  2021-07-13       Impact factor: 5.376

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.